Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for Lorlatinib-Associated Weight Gain in NSCLC
NCT07782359Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- Oct 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirzepatide, sponsored by University of Chicago. Primary endpoints: Body weight changes at 1 year, Lipid changes at 1 year and 3 more. Started Oct 2026; status: recruiting.
02
Drugs
Beyond the preview
Go deeper on NCT07782359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782359.